GHRP-2 (also known as pralmorelin) is a small synthetic peptide that mimics ghrelin, the body's natural hunger and growth-signaling hormone. It binds to the growth hormone secretagogue receptor (GHS-R) — the same receptor ghrelin uses — to trigger pulses of growth hormone release from the pituitary gland. Originally developed at Tulane University as part of a series of short, highly active GH-releasing peptides, GHRP-2 was studied clinically as a diagnostic agent for growth hormone deficiency and as a potential therapy for short stature and catabolic illness.
What makes GHRP-2 distinctive is its dual action: it both stimulates growth hormone secretion and increases appetite, mirroring ghrelin's two main physiological roles. It's orally active, works at low doses, and produces robust GH pulses across age groups and body types. Because it acts on a different receptor than GHRH (the body's primary GH-releasing signal), the two can be combined for synergistic effects — a property that has made GHRP-2 a useful research tool for probing how the GH axis is regulated.
GHRP-2 and Growth Hormone Release
GHRP-2's defining property is its ability to trigger pulses of growth hormone secretion. Studies in healthy subjects show that GHRP-2 reliably and substantially raises serum GH levels, with effects observable across age, sex, and body composition (5). In one clinical infusion study, subcutaneous GHRP-2 produced a roughly 13-fold increase in GH area-under-the-curve compared with saline (4).
The mechanism is receptor-specific. GHRP-2 acts through the GHS-R (the ghrelin receptor) rather than the GHRH receptor — work in transfected pituitary cells confirmed that GHRP-2 doesn't activate the GHRH receptor or its downstream cAMP signaling, even at high concentrations (8). However, the picture is more nuanced in intact tissue: experiments using antisense knockdown of receptor expression suggest that full GHRP-2-induced GH release depends on both GHS-R and a functional GHRH receptor system working together (7). This explains why combining GHRP-2 with GHRH produces synergistic, rather than merely additive, GH release — and why chronic dosing with either peptide can convert an additive response into a synergistic one (9). For research purposes, GHRP-2 has been used as a diagnostic provocation test, with a GH peak below 15 µg/L distinguishing GH-deficient subjects from healthy controls (5).
GHRP-2 and Appetite
Because GHRP-2 binds the ghrelin receptor, it also reproduces ghrelin's appetite-stimulating effect. In a controlled crossover study in lean, healthy men, a 270-minute subcutaneous infusion of GHRP-2 increased ad libitum food intake at a buffet meal by approximately 36% compared with saline — an effect seen in every participant (4). The macronutrient composition of food chosen didn't change; subjects simply ate more.
This was the first human evidence that a synthetic ghrelin mimetic could drive eating behavior the way ghrelin itself does. The finding is relevant in two directions: it positions GHRP-2 as a potential tool for conditions involving poor appetite, low body weight, or cachexia, and it flags appetite stimulation as a predictable effect to expect during use. Importantly, GH was rising at the same time food intake was — suggesting GHRP-2 produces a coordinated metabolic state that favors energy intake alongside anabolic signaling (4).
GHRP-2 and Muscle Preservation
Beyond its effects on circulating GH, GHRP-2 appears to act directly on muscle tissue. In studies of muscle wasting induced by the catabolic steroid dexamethasone, GHRP-2 attenuated the upregulation of two key muscle-breakdown enzymes — Atrogin-1 and MuRF1, both E3 ubiquitin ligases that tag muscle proteins for destruction (3). Strikingly, this protective effect occurred without changes in circulating IGF-I, the usual messenger of GH's anabolic effects, indicating GHRP-2 was working directly at the muscle cell level. In isolated muscle cell cultures, GHRP-2 suppressed Atrogin-1 and MuRF1 in a dose-dependent way, and the effect was blocked by a ghrelin receptor antagonist — confirming that muscle cells themselves carry GHS-R and respond to it (3).
Clinical work in critically ill men extends this picture. Five days of GHRP-2 infusion reactivated suppressed GH secretion and normalized IGF-I, IGFBP-3, and acid-labile subunit levels (6). Combining GHRP-2 with TRH and GnRH produced broader metabolic benefits — reduced protein breakdown and improved bone formation markers — suggesting GHRP-2 is most useful as part of a coordinated approach to restoring multiple hormonal axes in catabolic states (6).
GHRP-2 and Pharmacokinetics
GHRP-2 is active by multiple administration routes — subcutaneous, oral, intranasal, and buccal — which is unusual for a peptide and reflects its small size and resistance to first-pass breakdown (5). After nasal administration, GHRP-2 and its primary metabolites (GHRP-2 free acid and GHRP-2 (1-3) free acid) are detectable in urine for up to 47 hours, providing a clear window for analytical detection (1).
This pharmacokinetic profile has made GHRP-2 a target of anti-doping surveillance. The peptide has appeared in over-the-counter supplement products marketed to athletes — one analytical investigation found roughly 50 µg of GHRP-2 per tablet in a commercially available supplement, despite GHRP-2 being a prohibited substance (2). The detection methods developed around these findings rely on liquid chromatography paired with high-resolution mass spectrometry, and the detection window varies with dose, formulation, and individual metabolism (1, 2).